The link between CHIP and inflammatory cytokines is of particular interest with regard to the CANTOS trial where the monoclonal antibody canakinumab targeting IL-1β was found to significantly lower the rate of recurrent cardiovascular events in patients with previous myocardial infarction and a CRP level of ≥ 2 mg/L [80]. The gene discussed is STUB1; the disease is myocardial infarction.